Clinical Trials Logo
  1. Home
  2. X-linked Adrenoleukodystrophy
  3. NCT01787578

Safety and Pharmacodynamic Study of Sobetirome in X-Linked Adrenoleukodystrophy (X-ALD)

X-Linked Adrenoleukodystrophy Clinical Trial

Official title:
A Prospective Safety, Tolerance, Pharmacodynamics and Pharmacokinetics Study of Sobetirome in Male Subjects Diagnosed With X-linked Adrenoleukodystrophy (X-ALD)

Clinical Trial Summary

The purpose of this study is to assess the safety, tolerance, pharmacokinetics, and pharmacodynamics of sobetirome, a selective thyroid hormone analog, in adult male X-ALD patients.

Clinical Trial Description

Subjects will have a screening visit within 6 weeks prior to the Baseline visit. At Baseline visit blood will be drawn and to establish baseline values for plasma and red blood cell (RBC) very long chain fatty acids (VLCFA; C22, C24, and C26). Subjects will receive an oral dose of 50 mcg sobetirome once daily for 14 days beginning on Day 1. Subjects will be kept in the clinic on Day 1 for 16 hours following their initial dose of sobetirome for repeat blood sampling for pharmacokinetic analysis. Subjects will return to the clinic on days 7, 15, 21 and 28 for blood collection for VLCFA measurements. On day 15, after safety assessment, subjects will receive an increased dose of 100 mcg and this dose will be continued once daily through Day 28. Subjects will continue to return to the clinic weekly for blood and urine collection and safety assessments. Subjects will return to the clinic on day 42 for an End of Study visit that will involve a final measurement of VLCFA and blood and urine safety labs to check for reversibility. Safety labs will include serum chemistry, free fatty acid profile, hematology, urinalysis, and thyroid function. Subjects will be monitored with ECGs, vital signs, physical exams and assessment of adverse events. ;

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT01787578
Study type Interventional
Source Oregon Health and Science University
Contact
Status Withdrawn
Phase Phase 1
Start date April 2013
Completion date February 2014
View Details
See also
  Status Clinical Trial Phase
Not yet recruiting NCT05911919 - Validation of a Prognostic Biomarker Using Brain Diffusion MRI in X-linked Adrenoleukodystrophy
Recruiting NCT03727555 - Lentiviral Gene Therapy for X-ALD N/A
Completed NCT02595489 - A Pilot Study of Vitamin D in Boys With X-linked Adrenoleukodystrophy Phase 1
Completed NCT01594853 - Exercise Study of Function and Pathology for Women With X-linked Adrenoleukodystrophy N/A
Completed NCT04687007 - SMART-ALD - A New Lifestyle Intervention to Improve Quality of Life in Women With X-linked Adrenoleukodystrophy (X-ALD) N/A
Completed NCT01165060 - The Effect of Bezafibrate on the Level of Very Long Chain Fatty Acids (VLCFA) in X-linked Adrenoleukodystrophy (X-ALD) N/A
Recruiting NCT05939232 - Registry of X-linked Adrenoleukodystrophy
Active, not recruiting NCT02699190 - LeukoSEQ: Whole Genome Sequencing as a First-Line Diagnostic Tool for Leukodystrophies
Completed NCT03864523 - Effect of Pioglitazone Administered to Patients With Adrenomyeloneuropathy Phase 2
Recruiting NCT06178120 - Disease Progression in Women With X-linked Adrenoleukodystrophy
Recruiting NCT03278899 - A Study to Prospectively Assess Disease Progression in Male Children With X-ALD
Recruiting NCT03047369 - The Myelin Disorders Biorepository Project
Recruiting NCT04675749 - Quality of Life in Women With X-linked Adrenoleukodystrophy
Withdrawn NCT03196765 - Safety, Pharmacokinetics and Pharmacodynamics of NV1205 in Pediatric Male Subjects With Adrenoleukodystrophy Phase 1/Phase 2
No longer available NCT02233257 - Expanded Access for Lorenzo's Oil (GTO/GTE) in Adrenoleukodystrophy N/A